Substance use trends from urine drug testing in the United States, 2017-2025

Authors: White, Bradley; Skinner, Jonathan; Hammonds, Tracy; Bhattacharyya, Partha; Ali, Mir M

Source journal: Health affairs scholar (2026-11-01)

DOI: 10.1093/haschl/qxag291

Abstract

INTRODUCTION: Substance use in the United States has evolved substantially, shifting from prescription opioids toward synthetic opioids, stimulants, and marijuana. Timely surveillance is needed to characterize these changes and inform public health responses. This study examined substance use trends using urine drug testing (UDT) data from 2017 to 2025. METHODS: UDT data were analyzed for 3.34 million adults aged 18-64 across the nation. Monthly positive patient rates were calculated for alcohol, amphetamine, cocaine, heroin, marijuana, methamphetamine, prescription opioids, and synthetic opioids. National temporal trends were summarized, and state-level variation was mapped. RESULTS: Prescription opioid positivity declined from 33.7% in June 2017 to 18.4% in May 2025, while marijuana positivity increased from 21.5% to 31.3% and amphetamine positivity increased from 5.1% to 11.8%. Methamphetamine positivity rose to a peak in 2022 and then declined. Heroin and synthetic opioid positivity also declined over the study period, while alcohol and cocaine showed comparatively modest changes. Substantial geographic variation was observed, particularly for opioids and methamphetamine. CONCLUSION: UDT data reveal a changing US substance use landscape characterized by declining opioid and increasing marijuana and amphetamine positivity. Large-scale UDT data can complement traditional surveillance and inform regionally tailored prevention, treatment, and harm-reduction strategies.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.